Serotonin Transporter Gene Variants Tied to Heavier Side Effect Burden from Escitalopram

For millions of people living with major depressive disorder, the first weeks on an antidepressant can feel like a gamble. The medication that is supposed to lift the fog of depression may instead deliver nausea, insomnia, sexual dysfunction, or a cascade of other unwanted effects that force patients to abandon treatment before it has a chance to work. A new study from Pakistan now adds a genetic dimension to this familiar clinical dilemma, reporting that inherited variation in the serotonin transporter gene appears to shape how badly patients tolerate one of the world’s most widely prescribed antidepressants.

The research, published in BMC Psychiatry, followed 430 adults with newly diagnosed major depressive disorder who were starting treatment with escitalopram, a selective serotonin reuptake inhibitor, or SSRI. Over twelve weeks, the team tracked both the emergence and the severity of adverse effects, and then asked a deceptively simple question: could differences in a single gene explain why some patients sail through treatment while others struggle? The answer, according to the data, appears to be yes, at least in part.

The gene at the center of the study is SLC6A4, which encodes the serotonin transporter, the molecular pump that sweeps the neurotransmitter serotonin back out of the synapse after it has delivered its chemical message. This transporter is the direct target of escitalopram and its SSRI cousins, which block the pump and leave more serotonin circulating between neurons. Because the drug’s entire mechanism depends on binding to this protein, variation in the gene that builds it has long been a prime suspect in the search for the roots of inter-individual differences in antidepressant response and tolerability.

Two linked variants within SLC6A4 formed the genetic focus of the work. The first is 5-HTTLPR, a repetitive stretch of DNA in the gene’s regulatory region that exists in a short (S) and a long (L) version. The short allele is associated with reduced production of the transporter, meaning less of the serotonin pump is made and deployed at the synapse. The second variant, rs25531, sits within the long allele itself and subdivides it into functional subtypes: the L_A version behaves like a normal high-expression allele, while the L_G version carries a single-letter change that suppresses transporter expression, effectively making it functionally short. Researchers therefore group individuals into functional categories, conventionally labeled 0L, 1L, and 2L, that reflect how many high-expression transporter alleles each person carries.

To determine each participant’s genotype, the team used polymerase chain reaction to amplify the 5-HTTLPR region and separated the resulting DNA fragments by agarose gel electrophoresis, distinguishing the SS, SL, and LL genotypes by fragment size. The rs25531 variant was resolved through restriction fragment length polymorphism analysis, a technique in which a bacterial enzyme cuts the amplified DNA only when the specific nucleotide variant is present, producing a characteristic pattern of fragments that reveals which subtype of the long allele a person carries. This combined genotyping allowed the investigators to classify participants both by biallelic genotypes and by the more biologically meaningful functional groups.

The clinical picture that emerged was striking. Of the 430 participants, 253, or 58.8 percent, experienced clinically significant adverse effects during the twelve-week follow-up. Side effects were systematically assessed with the UKU Side Effect Rating Scale, a validated instrument developed for psychotropic medications that covers psychological, neurological, autonomic, and other symptom categories. Ratings were collected at baseline and again at weeks four, eight, and twelve, and for the primary analysis the researchers used the maximum UKU score recorded at any point, a design choice intended to capture side effects occurring at any stage of treatment rather than only at a single snapshot in time.

When the researchers stratified these adverse-effect scores by genotype, a consistent pattern appeared. Participants carrying the short S allele, and more broadly those in the 0L functional group, which includes individuals with SS, SL_G, and L_G L_G genetic combinations, bore a significantly greater burden of escitalopram-related side effects. At the opposite end of the spectrum, carriers of the L_A L_A combination, the 2L functional group with two fully functional high-expression alleles, recorded comparatively lower UKU scores. The associations held across the different analytical framings, whether the team examined biallelic genotypes, diplotypes combining both polymorphisms, or the functional groupings, and they remained statistically significant.

The biological logic behind this gradient is plausible, though the study’s observational design means causation cannot be proven. One leading hypothesis is that people with lower transporter expression start with less serotonin clearance capacity, and when escitalopram further inhibits the transporter they experience a more pronounced serotonergic surge, which may translate into a heavier load of serotonergic side effects. Alternatively, the same genetic variants could influence drug exposure or downstream signaling in ways not yet fully mapped. What the study establishes firmly is an association: in this Pakistani cohort, the number of functional transporter alleles a patient inherited tracked with how much trouble they had tolerating the drug.

The implications reach into one of the most frustrating gaps in modern psychiatry. Escitalopram and other SSRIs are prescribed on a largely trial-and-error basis, and adverse effects are a leading reason patients stop taking medication, contributing to the high rates of treatment non-adherence seen in depression care. If genetic screening for 5-HTTLPR and rs25531 could identify patients likely to struggle with escitalopram before the first tablet is swallowed, clinicians might choose a different agent or adjust their monitoring accordingly. The authors suggest that these variants warrant further investigation as potential pharmacogenetic markers, though they are careful to note that such clinical translation remains premature.

Indeed, the study comes with important caveats that temper any temptation to order a genetic test tomorrow. As an observational analysis, it cannot establish that the polymorphisms cause the differences in tolerability. The work examined only escitalopram and a selected set of SLC6A4 variants, leaving out other pharmacogenetic factors, most notably variations in CYP2C19, the liver enzyme responsible for metabolizing escitalopram, as well as environmental influences on drug response. The twelve-week follow-up also means that longer-term or delayed adverse effects were not evaluated. The authors themselves emphasize that prospective studies in independent populations are needed to confirm reproducibility and to determine whether the association carries real clinical weight. Still, for a field where the first prescription is often a shot in the dark, the finding that a well-characterized serotonin transporter variant flags patients at higher risk of side effects is a meaningful step toward a more personalized approach to depression treatment, and a reminder that the genetics of drug tolerability deserves the same attention long given to drug efficacy.

Subject of Research: Association between SLC6A4 5-HTTLPR/rs25531 polymorphisms and escitalopram adverse effects in major depressive disorder

Article Title: Association of 5-HTTLPR/rs25531 polymorphism with escitalopram induced adverse effects in Pakistani patients of Major Depressive Disorder

Article References: Afridi, M. F., Haq, I. U., Zakki, S. A., Rafiullah, R., Khan, G. A., Akhtar, S., Kolhar, M., & Muhammad, J. (2026). Association of 5-HTTLPR/rs25531 polymorphism with escitalopram induced adverse effects in Pakistani patients of Major Depressive Disorder. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08595-9

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08595-9

Keywords: 5-HTTLPR, rs25531, SLC6A4, escitalopram, SSRI, pharmacogenetics, major depressive disorder, adverse effects, serotonin transporter, UKU Side Effect Rating Scale, Pakistan, genetic association study